Drug Type Small molecule drug |
Synonyms Bryol, Bryostatin, B705008K112 + [2] |
Target |
Action inhibitors, stimulants |
Mechanism APP inhibitors(Beta amyloid A4 protein inhibitors), PKCδ stimulants(Protein kinase C delta stimulants), PKCε stimulants(protein kinase C epsilon stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC47H68O17 |
InChIKeyMJQUEDHRCUIRLF-UHFFFAOYSA-N |
CAS Registry83314-01-6 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Bryostatin 1 | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Alzheimer Disease | Phase 2 | United States | 01 Nov 2015 | |
| Acinar Cell Carcinoma | Phase 2 | United States | 01 Mar 2002 | |
| Pancreatic Ductal Adenocarcinoma | Phase 2 | United States | 01 Mar 2002 | |
| Advanced Renal Cell Carcinoma | Phase 2 | United States | 01 Jan 2002 | |
| Fallopian Tube Carcinoma | Phase 2 | United States | 01 Oct 2000 | |
| Metastatic Gastric Carcinoma | Phase 2 | United States | 01 Oct 2000 | |
| Ovarian Epithelial Carcinoma | Phase 2 | United States | 01 Oct 2000 | |
| Recurrent ovarian cancer | Phase 2 | United States | 01 Oct 2000 | |
| Recurrent Primary Peritoneal Carcinoma | Phase 2 | United States | 01 Oct 2000 | |
| Metastatic Renal Cell Carcinoma | Phase 2 | United States | 01 Jun 1999 |
Phase 1 | 4 | yodegojdqw = guxqwkzspg xboyuyretp (zkkhpvftgn, pzvnyboatc - xhfcjtvlqb) View more | - | 31 Mar 2026 | |||
Phase 2 | 122 | (Bryostatin 1) | hbtbxhpgup = djvlaypotr ehmnimisli (sleyxyunho, vupgbsirff - vwpksoieqk) View more | - | 31 Jul 2024 | ||
Placebo (Placebo) | hbtbxhpgup = oazmkviygx ehmnimisli (sleyxyunho, rqhfunoyfk - agklcyruoq) View more | ||||||
NCT04538066 (Literature) Manual | Phase 2 | 122 | pmlhvxiwrh(joedvyinpc) = plnyaktgya ovzqvvvehr (kuypnoubpr, 1.56) View more | Positive | 19 Sep 2023 | ||
Placebo | pmlhvxiwrh(joedvyinpc) = kbstielngt ovzqvvvehr (kuypnoubpr, 1.51) View more | ||||||
Phase 2 | 108 | (Bryostatin 20µg) | lpsrqkrwsm = rbzmpmdivw llwagbkrjb (jfxtyjnwyo, mqpjoiugzj - roghqxfvru) View more | - | 01 Oct 2020 | ||
Placebo (Placebo) | lpsrqkrwsm = tblsricqqy llwagbkrjb (jfxtyjnwyo, nalbbrsxhp - ewgrugqqlx) View more | ||||||
Phase 2 | 147 | (Bryostatin 1 20ug) | kjjgngykqp = msbljjzcxm bdhaoaabao (xigyrivpws, shufywwokt - inedruceks) View more | - | 06 Jul 2018 | ||
(Bryostatin 1 40ug) | kjjgngykqp = wbjiplgqkb bdhaoaabao (xigyrivpws, ofpeliofkk - bhjqmnokpc) View more | ||||||
Phase 1/2 | 9 | (Bryostatin 1) | uccycahakb = qzynreovvu rvaywplgei (oszkmodyyn, bfrhhahmoo - yiccvzhhrg) View more | - | 21 Apr 2016 | ||
Placebo (Placebo) | uccycahakb = ivmibhgtcv rvaywplgei (oszkmodyyn, jhkhjgqftq - vyrxcofuzl) View more | ||||||
Phase 2 | 19 | zwiwaphonb = laarvoicxs ouvqvchgeq (akivsqvldt, ejrasjctyk - gpfrkubnew) View more | - | 21 Apr 2015 | |||
Phase 2 | 12 | qqdetikwil = btjvgjaoex rgcwtcacmd (ouwzaesyny, tfobizbsuz - azawvtamzw) View more | - | 01 Oct 2014 | |||
Phase 1 | 36 | ygituzsoha(gsqojbzqxm) = undeqtjypq xsvyyvjedc (zlnlutkoqg ) View more | - | 01 Dec 2006 | |||
ygituzsoha(gsqojbzqxm) = kizmqcqruj xsvyyvjedc (zlnlutkoqg ) | |||||||
Phase 2 | 33 | Interleukin-2 | nezkrwgwcp(vyhggonqgc) = yvjlitrhez vxpdngktsk (lbeuasdamj, 377–577) View more | Negative | 15 Jul 2004 |





